Background: This study aimed to develop an easy to use prediction model to predict the risk of having a total of 1 to 2, ≥3, or ≥4 positive axillary lymph nodes (LNs), for patients with sentinel lymph node (SLN) positive breast cancer. Methods: Data of 911 SLN positive breast cancer patients were used for model development. The model was validated externally in an independent population of 180 patients with SLN positive breast cancer. Results: Final pathology after ALND showed additional positive LN for 259 (28%) of the patients. A total of 726 (81%) out of 911 patients had a total of 1 to 2 positive nodes, whereas 175 (19%) had ≥3 positive LNs. The model included three predictors: the tumor size (in mm), the presence of a negative SLN, and the size of the SLN metastases (in mm). At external validation, the model showed a good discriminative ability (area under the curve = 0.82; 95% confidence interval = 0.74-0.90) and good calibration over the full range of predicted probabilities.
| INTRODUCTION
The axillary treatment of breast cancer has changed significantly over time. After the implementation of the sentinel lymph node biopsy (SLNB) procedure, only patients with sentinel lymph node (SLN) metastases were selected for treatment by a completion axillary lymph node dissection (ALND). The IBCSG 23-01 study showed that a completion ALND could be omitted for patients with micrometastases. 1 Furthermore, the ACOSOG Z0011 trial showed that for a selected subgroup of patients, a small volume of disease left behind in the axilla does not compromise the oncological safety, in terms of recurrence and disease-free and overall survival. 2 Also, the results of the AMAROS trial, published in 2014, changed our perspective on axillary treatment showing that both radiotherapy, as well as surgery, can provide excellent regional control. 3 These studies have had a significant impact on the management of the axilla. 4 It is obvious that the trend is heading towards a less invasive surgical treatment of the axilla. ALND has lost its importance for determining the need of adjuvant systemic treatment 4, 5 and gradually seems to lose its importance for locoregional control.
However, there remain several subgroups of breast cancer patients for whom treatment of the axilla may still be necessary.
These include patients who were found to be node positive with ultrasound-guided lymph node biopsy (UGLNB). This appears to be a different group of node-positive patients with less favorable disease characteristics and a worse disease-free and overall survival as compared with those with SLN positive disease. 6, 7 Another group may be the patients who are treated with a mastectomy rather than breast-conserving surgery (BCS), as radiotherapy may partially include the axilla when used as adjuvant treatment after BCS. 8 In the last decade, the focus was set on finding patients with SLN positive breast cancer with a low risk of additional nodal involvement, for whom a completion ALND could be omitted. Several predictive systems have been developed to help identifying such patients. [9] [10] [11] [12] [13] [14] [15] [16] [17] Now that also a low risk of limited nodal involvement is increasingly accepted to omit further axillary treatment, it is time to search for the patients at high risk for extensive nodal involvement who may still benefit from additional treatment of the axilla.
Presently, three predictive models have been proposed, that predict the risk of having four or more positive axillary lymph nodes (LNs). [18] [19] [20] The main purpose of these models is to help decide on the extent of radiation and/or systemic therapy and whether an immediate breast reconstruction can be offered to these patients. [18] [19] [20] To our knowledge, there is no model, that predicts the extent of nodal involvement.
The aim of the present study was to develop a tool for predicting the extent of nodal involvement in node-positive breast cancer patients. Such a tool may then be used for counseling in the clinical decision-making process, in the present "treat none-unless" era, regarding the additional axillary treatment strategies.
| METHODS

| Study population
The study population consisted of three consecutively selected December 2011. 6 In accordance with Dutch guidelines 21 all patients had sonographic evaluation of the axilla after mammography and clinical evaluation. UGLNB (with cytological and/or histological sampling) was performed on suspicious axillary LNs as previously described. 6 All patients included in the present study underwent a completion ALND. Patients receiving neoadjuvant treatment, those with stage IV breast cancer and patients with a clinical N 2-3 axillary status or without a completion ALND were excluded from the study. 
| Data accrual
| Predictors and model development
Candidate predictors for axillary lymph node involvement were included in the analysis based on the literature and previously reported models. These included the models that predict the risk of having four or more involved axillary LNs. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] We developed a model to predict the number of positive non-SLNs, and thus the total number of positive LNs. We used proportional-odds-logisticregression-analysis to model the association between predictors and the number of positive non-SLNs. We checked the proportional-odds-assumption graphically for all potential predictors. We evaluated the strength of each predictor by its univariable odds ratio, and by its multivariable odds ratio together with its likelihood ratio χ 2 test statistic minus twice the degrees of freedom. The latter is consistent with Akaikeʼs information criterion which balances the goodness-of-fit of a model with its complexity, and was also used to select predictors into a final model. 24 The patients in the UGLNB-group were also analyzed as described before, because we wanted to provide predictions for all node-positive breast cancer patients, regardless of the method of the detection. However, the analysis showed no additional predictors that could discriminate between low and high-risk patients because the method of detection was the strongest predictor for extensive nodal involvement. Consequently, we did not develop a separate model and only the overall probabilities of having a total of 1 to 2, ≥3, or ≥4 positive LNs were derived from the present dataset.
| Presentation of the prediction model
For easy calculation of the probability of having a particular number of positive LNs, we presented the final model with a score chart based on the regression coefficients of the final proportional odds model. 24, 25 Predictor values were translated into a sum score that can be used to read the probability of having a total of 1 to 2, ≥3, or ≥4 positive LNs from a Table, given the number of positive SLNs.
| Validation of the new prediction model
We validated predictions of having ≥3 positive LNs for patients with <3 positive SLNs within the development data and the external validation data. We used validation plots to visualize the performance of the model. 26 The ability of our model to predict ≥4 positive LNs was compared with the previously developed nomograms by Katz et al, [18] [19] [20] We assessed the calibration of our model by the calibration slope and the calibration-in-the-large. 25 We assessed the discriminative ability by the area under the curve (AUC) of the receiver operating characteristic curve. Since we are assessing predictions of binary outcomes, the AUC is equal to the c-index, which estimates the probability that the risk prediction of a randomly chosen patient with the outcome is higher than the risk prediction of a randomly chosen patient without the outcome. Of these, 175 (19%) had a total of three or more involved axillary LNs (Table 1 ). The observed overall proportions of patients in the UGLNB-group with a total of 1 to 2, ≥3, or ≥4 positive LNs were 37%, 63%, and 51%, respectively.
Meretoja et al, and Chagpar et al
| Predictors and model development
The univariable analysis showed the following significant predictors for additional axillary lymph node involvement: tumor size (mm), tumor grade, LVI, presence of a negative SLN, >1 positive SLN, SLN macrometastases, an SLN metastases size >5 mm, and the presence of extracapsular extension. Predictor effects of age >65-year mulitfocality of the tumor, invasive lobular carcinoma morphology, a positive ER status, a positive PR status, and a positive Her2Neu status were nonsignificant but in the expected direction ( Table 2) . 
| 581
The proportional odds assumption was well satisfied upon graphical inspection. The effects of the predictors were reasonably constant across any cut-off level for the extent of lymph node positivity ( Figure S1 , the constant horizontal distance between any two of the three symbols). Table 3 .
The regression coefficients in a complete case analysis of the full model (n = 301) were very similar to the analyses based on imputed data. Furthermore, none of the other variables were identified as predictive in the complete case analysis. (Table S1 ).
| Presentation of the prediction model
In the final model the following three predictors were selected: the size of the tumor in mm, the presence of a negative SLN, and the size of the SLN metastases in mm ( Table 3 ). The model is presented as a simple score chart (Figure 1 ). For example, a patient with an SLN metastasis size of 8 mm, a tumor size of 25 mm, and no negative SLN has predicted probabilities of 73%, 27%, and 17% of having a total of 1 to 2, ≥3, or ≥ 4 positive LNs, respectively. The effect of extracapsular extension appeared to be nonsignificant after backward selection (P = .12), and the impact of adding ECE to the model was thus negligible. 
| Validation of the prediction model
| Comparison with previously developed models
When predicting the probability of having ≥4 positive LNs (for patients with less than four positive SLNs), the discriminative ability of our new model was equally good or even better in the external validation data (AUC = 0.82; 95% CI = 0.74-0.90) as compared with the three previously developed predictive systems (18-20) (AUCʼs of 0.82, 0.80, and 0.66, respectively). Furthermore, calibration was also superior for the newly developed prediction model ( Figure S3 ).
| DISCUSSION
Early stage breast cancer patients, with limited nodal involvement, are no longer subjected to a completion ALND, based on the results of the IBCSG 23-01, AMAROS, and Z0011 trials. [1] [2] [3] Because the evidence for omitting further axillary treatment in patients with extensive nodal involvement is lacking, it is useful to predict the extent of nodal involvement.
We have developed a novel model that predicts the risk of having a total of 1 to 2, ≥3, or ≥4 positive LNs using only three predictors:
tumor size (in mm), the presence of a negative SLN and the size of the SLN metastases (in mm). Although the presence of extracapsular extension also showed to be a significant predictor in both univariable and multivariable analysis we chose to incorporate only the three strongest predictors. This did not affect model performance and was in line with the aim of this study to keep the model as simple and user-friendly as possible. The discriminative ability of the model was good (AUC of 0.80) and it showed adequate calibration over the complete range of predicted probabilities. Furthermore, the model was validated in an independent external patient population and showed good discrimination (AUC 0.82) and calibration.
Because we wanted to provide risk predictions for all nodepositive breast cancer patients, regardless of the method of detection, also an UGLNB-group was analyzed. However, when the lymph node metastases are detected by ultrasound, this staging method by itself seems to be the most important predictor for extensive nodal involvement given the fact that 63% of these patients had ≥3 positive LNs. These findings are in concordance with the results of Schipper et al 27 , that showed that the finding of suspicious nodes with ultrasound resulted in pN2-pN3 disease in 41.2% of the patients. For this patient group, we found no additional predictors that could further discriminate between low-and high-risk patients. Consequently, we decided that the development of a separate model for this group was not relevant. Because these patients also need counseling regarding the axillary treatment strategy, the overall risk estimates of having a total of 1 to 2, ≥3, or ≥4 positive LNs are also visualized in our prediction tool.
Previously published models were mostly developed before the publication of the Z0011-trial results and are intended to identify patients at low risk for additional nodal involvement for whom a completion ALND could be omitted. [9] [10] [11] [12] [13] [14] 16, 17 The few models that have been designed to predict the risk of having ≥4 involved LNs were used to guide decisions on the extent of radiation and systemic therapy regimens. [18] [19] [20] To our knowledge our model is the first that actually predicts the extent of nodal involvement, therefore easily classifying patients to have limited nodal involvement (1-2 positive LNs, corresponding to the conclusions of Z0011) or extensive lymph node involvement (≥3 positive LNs). Although it was not a primary goal of this study, our model also predicts the risk of having ≥4 positive LNs. This is another cut-off-point for extensive nodal involvement that is used to decide about the need for additional axillary irradiation. The new model was compared with the existing three models that predict ≥4
positive LNs and outperformed the other models in terms of discriminative ability and calibration for our Dutch population.
The variables included in our new prediction tool already proved to be strongly associated with nodal involvement in other models and validation studies. Furthermore, other previously reported models included up to nine variables, resulting in more complex calculations and a less user-friendly model. 15 The present study shows that model performance can still be very good when only a few but strongly prognostic variables are included.
Our study has limitations. A retrospectively collected database was used that contained some missing values. The size of the SLN metastases (in mm) is a strong predictor for extensive nodal involvement, however, the actual size was not always provided.
Although our model also works based on the presence or absence of a macrometastasis in the SLN, with acceptable model performance,
we recommend that the actual size of the SLN metastases should be reported consistently by pathologists to enable more accurate predictions. The risk predictions for patients that were found node positive by UGLNB are based on relatively small sample size.
Therefore, we are currently investigating whether these risks will be similar in a larger population.
Some clinicians have already abandoned the use of ALND for SLN positive patients. However, we must be aware of the generalization of the conclusions of the Z0011-trial, as these are only applicable to about 6% of the total breast cancer population. 28 F I G U R E 1 Score chart for the probability of finding a total of 1 to 2, ≥3, or ≥4 positive lymph nodes. For example, in a patient with one positive sentinel lymph node (SLN) with a largest size of the metastasis of 8 mm, a tumor size of 25 mm, and no negative SLN found, the score is calculated as follows: [8] (8 mm largest metastasis size) + [0.25 × 25] (25 mm tumor size) + [5] (if no negative SLN was found), which makes a (rounded) sum score of 19 points. The probabilities can then be read from the chart on the horizontal line following the 19 (sum score). The probability of having only 1 to 2 nodes positive is 73%, the risk of having ≥3 positive lymph nodes is 27% and the risk of having ≥4 is 17%. For a similar patients with a negative SLN the sum score would be 14: | 585
